Bradykinin down-regulates, whereas arginine analogs up-regulates, endothelial nitric-oxide synthase expression in coronary endothelial cells.
Bradykinin (BK) is an endogenous vasoactive peptide that promotes vasodilation by stimulating the release of nitric oxide (NO) from endothelial cells via activation of endothelial NO synthase (eNOS). Although the role of BK in modulation of eNOS activity is well understood, its possible effect on eNOS expression remains uncertain. Several studies have demonstrated negative feedback regulation of eNOS by NO. Therefore, we hypothesized that sustained stimulation with BK may down-regulate eNOS expression in endothelial cells. Human coronary endothelial cells were incubated for 24 h with either BK alone or BK plus BK receptor type 1 or type 2 blockers. NO production and eNOS abundance (Western analysis) were determined. In separate experiments, cells were incubated with either an NOS inhibitor alone or in combination with BK. Incubation with BK caused a concentration-dependent rise in NO production and a dose-dependent decline in eNOS protein expression. These effects were abrogated by BK-2 blockade but unaffected by BK-1 blockade. In contrast, NOS inhibitors lowered NO production and raised eNOS abundance in a dose-dependent fashion. The effects of BK on NO production and eNOS expression were abrogated by the NOS inhibitor. Thus, sustained activation of eNOS by BK results in a compensatory down-regulation of eNOS, whereas its sustained inhibition leads to a compensatory up-regulation of eNOS. The observed modulations of eNOS expression are mediated by NO and represent an adaptive physiologic response.
Vaziri
N D
ND
Division of Nephrology and Hypertension, Department of Medicine, University of California, Irvine, California, USA. ndvaziri@uci.edu
Ding
Y
Y
Ni
Z
Z
Barton
C H
CH
D001120:Arginine / Q000031:analogs & derivatives* / Q000494:pharmacology*; D015153:Blotting, Western; D001920:Bradykinin / Q000494:pharmacology*; D002478:Cells, Cultured; D003331:Coronary Vessels / Q000166:cytology / Q000187:drug effects / Q000378:metabolism*; D015536:Down-Regulation / Q000187:drug effects; D042783:Endothelial Cells / Q000187:drug effects / Q000201:enzymology / Q000378:metabolism*; D004791:Enzyme Inhibitors / Q000494:pharmacology; D006801:Humans; D009569:Nitric Oxide / Q000096:biosynthesis / Q000502:physiology; D019001:Nitric Oxide Synthase / Q000037:antagonists & inhibitors / Q000096:biosynthesis*; D052250:Nitric Oxide Synthase Type III; D043783:Receptor, Bradykinin B1 / Q000187:drug effects; D043782:Receptor, Bradykinin B2 / Q000187:drug effects; D015854:Up-Regulation / Q000187:drug effects; D019323:omega-N-Methylarginine / Q000494:pharmacology
D004791:Enzyme Inhibitors; D043783:Receptor, Bradykinin B1; D043782:Receptor, Bradykinin B2; D019323:omega-N-Methylarginine; D009569:Nitric Oxide; D001120:Arginine; C496314:NOS3 protein, human; D019001:Nitric Oxide Synthase; D052250:Nitric Oxide Synthase Type III; D001920:Bradykinin